Chlorambucil for the treatment of patients with chronic lymphocytic leukaemia, or small lymphocytic lymphoma

To assess the effect of chlorambucil compared to other therapeutic regimens on overall survival, progression free survival, and response rates in patients with CLL/SLL requiring therapy. We will include patients receiving chlorambucil as first-line therapy and patients with relapsed or refractory CLL/SLL receiving salvage therapy with chlorambucil.

This is a protocol.